 |
PDBsum entry 1hii
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase (aspartic proteinase)
|
PDB id
|
|
|
|
1hii
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
E.C.3.4.23.47
- HIV-2 retropepsin.
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
3:381-389
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.
|
|
J.P.Priestle,
A.Fässler,
J.Rösel,
M.Tintelnot-Blomley,
P.Strop,
M.G.Grütter.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: The human immunodeficiency virus (HIV) is the causative agent of
acquired immunodeficiency syndrome (AIDS). Two subtypes of the virus, HIV-1 and
HIV-2, have been characterized. The protease enzymes from these two subtypes,
which are aspartic acid proteases and have been found to be essential for
maturation of the infectious particle, share about 50% sequence identity.
Differences in substrate and inhibitor binding between these enzymes have been
previously reported. RESULTS: We report the X-ray crystal structures of both
HIV-1 and HIV-2 proteases each in complex with the pseudosymmetric inhibitor,
CGP 53820, to 2.2 A and 2.3 A, respectively. In both structures, the entire
enzyme and inhibitor could be located. The structures confirmed earlier modeling
studies. Differences between the CGP 53820 inhibitory binding constants for the
two enzymes could be correlated with structural differences. CONCLUSIONS: Minor
sequence changes in subsites at the active site can explain some of the observed
differences in substrate and inhibitor binding between the two enzymes. The
information gained from this investigation may help in the design of equipotent
HIV-1/HIV-2 protease inhibitors.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. The pseudosymmetrical HIV protease inhibitor CGP
53820. Cha refers to the cyclohexyl ‘side chain’ which binds
in the P1′ pocket of HIV protease. Figure 2. The
pseudosymmetrical HIV protease inhibitor CGP 53820. Cha refers
to the cyclohexyl ‘side chain’ which binds in the P1′
pocket of HIV protease.
|
 |
Figure 6.
Figure 6. Stereo illustration of the binding of CGP 53820
(green) to HIV-1 protease (red) superimposed with HIV-2 protease
(blue) in complex with CGP 53820 (yellow). Figure 6. Stereo
illustration of the binding of CGP 53820 (green) to HIV-1
protease (red) superimposed with HIV-2 protease (blue) in
complex with CGP 53820 (yellow).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(1995,
3,
381-389)
copyright 1995.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
F.Ceccherini-Silberstein,
F.Erba,
F.Gago,
A.Bertoli,
F.Forbici,
M.C.Bellocchi,
C.Gori,
R.D'Arrigo,
L.Marcon,
C.Balotta,
A.Antinori,
A.D.Monforte,
and
C.F.Perno
(2004).
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure.
|
| |
AIDS,
18,
F11-F19.
|
 |
|
|
|
|
 |
P.Colson,
M.Henry,
C.Tourres,
D.Lozachmeur,
H.Gallais,
J.A.Gastaut,
J.Moreau,
and
C.Tamalet
(2004).
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
|
| |
J Clin Microbiol,
42,
570-577.
|
 |
|
|
|
|
 |
A.Raja,
J.Lebbos,
and
P.Kirkpatrick
(2003).
Atazanavir sulphate.
|
| |
Nat Rev Drug Discov,
2,
857-858.
|
 |
|
|
|
|
 |
B.Rodés,
A.Holguín,
V.Soriano,
M.Dourana,
K.Mansinho,
F.Antunes,
and
J.González-Lahoz
(2000).
Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.
|
| |
J Clin Microbiol,
38,
1370-1374.
|
 |
|
|
|
|
 |
L.Hong,
X.C.Zhang,
J.A.Hartsuck,
and
J.Tang
(2000).
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
|
| |
Protein Sci,
9,
1898-1904.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Munshi,
Z.Chen,
Y.Yan,
Y.Li,
D.B.Olsen,
H.B.Schock,
B.B.Galvin,
B.Dorsey,
and
L.C.Kuo
(2000).
An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
|
| |
Acta Crystallogr D Biol Crystallogr,
56,
381-388.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.B.Rose,
C.S.Craik,
and
R.M.Stroud
(1998).
Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
|
| |
Biochemistry,
37,
2607-2621.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.M.Towler,
S.K.Thompson,
T.Tomaszek,
and
C.Debouck
(1997).
Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity.
|
| |
Biochemistry,
36,
5128-5133.
|
 |
|
|
|
|
 |
S.S.Hoog,
E.M.Towler,
B.Zhao,
M.L.Doyle,
C.Debouck,
and
S.S.Abdel-Meguid
(1996).
Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
|
| |
Biochemistry,
35,
10279-10286.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |